Kim M. Hirshfield, MD, PhD
Hirshfield* KM, Bond* G, Kirchhoff, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine A. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Research, 66:5104-10, 2006. * denotes equal contribution by authors
Hirshfield, KM. Personalizing medicine through targeted agents, capitalizing on pathway dysregulation and biomarker use. Personalized Medicine, 5(6): 575-577, 2008.
Kulkarni D, Vazquez A, Haffty B, Bandera E, Hu W, Sun Y, Toppmeyer D, Levine A, Hirshfield KM. A polymorphic variant in MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis, 30:1910-5, 2009.
Das KM, Kong Y, Bajpai M, Kulkarni D, Geng X, Mishra P, Banerjee D, Hirshfield, KM. Transformation of benign Barrett’s epithelium by repeated acid and bile exposure over 65 weeks: A novel in-vitro model. International Journal of Cancer, 128:274-82, 2010.
Mehta MS, Vazquez A, Kulkarni DA, Kerrigan JE, Atwal G, Metsugi S, Toppmeyer DL, Levine AJ, Hirshfield KM. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Research and Treatment, 125:861-8, 2010.
Hirshfield KM, Rebbeck TR, Levine A. Germline mutations and polymorphisms in the origins of cancers in women. Journal of Oncology, 2010:297671, 2010.
Vazquez A, Kulkarni D, Grochola LF, Bond GL, Barnard N, Toppmeyer DL, Levine AJ, Hirshfield KM.
Haffty BG, Goyal S, Green C, Schiff D, Yang Q, Moran MS, Kulkarni D, Ganesan S, Hirshfield KM.
Chandran U, Hirshfield KM, Bandera EV. The role of anthropometric and nutritional factors on breast cancer risk in African American women: A systematic review. Public Health Nutrition 15(4): 738-48, 2012.
Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, Dipaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A. Cell Death Dis, 4:e877. doi: 10.1038/cddis.2013.393, 2013.
Dolfi S, Chan LLY, Qiu J, Hirshfield KM, Oltvai ZN, Vazquez A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates: implications for cancer therapies targeting metabolism. :20 doi:10.1186/2049-3002-1-20, 2013.
Dolfi SC, Jäger AV, Hait WN, Haffty B, Yang JM, Hirshfield KM. Fulvestrant Treatment Alters MDM2 Protein Turnover and Sensitivity of Human Breast Carcinoma Cells to Chemotherapeutic Drugs. Cancer Letters, doi: 10.1016/j.canlet.2014.04.009, 2014. [Epub ahead of print]
Hirshfield KM, Ganesan S. Triple Negative Breast Cancer: Molecular Subtypes and Targeted Therapy. Current Opinion in Obstetrics and Gynecology, 26(1): 34-40, 2014.